Generex Biotechnology (GNBT): Nice Wild Speculation
Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery for metabolic diseases through the inner lining of the mouth". Not a leader, the leader. Today, a small investment bank outfit called Rodman and Renshaw opened coverage on the…
Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery for metabolic diseases through the inner lining of the mouth". Not a leader, the leader. Today, a small investment bank outfit called Rodman and Renshaw opened coverage on the company with a "market outperform" rating.
The investment house said: "Our analysis indicates that Generex’s oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn’s product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013."
That’s right,"could result" in 2013. The stock moved up 42% to $1.79.
For the present, the company had $45,000 in revenue in the last reported quarter. The company’s operating loss for that period was $5.5 million.
Talk about a risky investment.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.




